Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,548.00
(
1.89%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,355.52
(
-0.15%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

nuere

Send PM Follow Ignore
Followers 4
Posts 359
Boards Moderated 0
Alias Born 08/17/2004

nuere

Re: DewDiligence post# 45485

Friday, 04/20/2007 8:29:45 AM

Friday, April 20, 2007 8:29:45 AM

Post# of 257443
OXGN
I’m going to go out on a limb and predict that this quadruplet regimen (Avastin + CA4P + dual chemo) will prove to be too toxic, and that such a regimen will never be used commercially. Regards, Dew

With the proper dosing schedule I think this combination is possible. Kerbel has done some preclinical work (Science sep 06)that probably will form the basis for this scheduling.
Regards
nuere
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today